Drug Trial Radar · NCT07643233
Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions
Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Jul 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- AJU Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 54 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate and compare the safety and pharmacokinetic profiles of "AJU-G721" (test drug) and "G721R" (reference drug) in healthy adult male subjects.
Conditions
- Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Interventions
Test DrugDrug
AJU-G721
Reference DrugDrug
G721R
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of Tamsulosin.Time frame: 0 hour ~ 48 hour after drug administration
- AUCt of TamsulosinTime frame: 0 hour ~ 48 hour after drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bumin Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.